Rheumatoid arthritis

Just as with the bioactivity against autoimmune diseases, clinical studies in preclinical stages suggest that artemisinin and its derivatives possess crucial properties that could be useful to treat inflammatory diseases such as rheumatoid arthritis, a disease that affects approximately 1% of the global population. Several studies also suggest that other secondary metabolites with anti-inflammatory properties present in the leaves of Artemisia annua, such as beta-caryophyllene, cirsilineol, 6-methoxytricin or apigenin also facilitate the solubility and effectiveness of artemisinin, which in conjunction would have incremental beneficial effects.

References: